

①⑨ FEDERAL REPUBLIC  
OF GERMANY



GERMAN  
PATENT OFFICE

①⑫ **Laid-open Specification**

①⑪ **DE 38 32 056 A1**

⑤① Int. Cl.<sup>5</sup>:  
A 61 K 35/78

②① Application Number: P 38 32 056.8

②② Date Filed: 9/21/88

④③ Date Laid Open: 3/22/90

⑦① Applicant:  
Scholle, Helmut, Dr. med.,  
3300 Brunswick, DE

⑦④ Representative:  
Gramm, W., Prof. Graduate Engineer,  
Lins, E., Graduate Physicist,  
Patent attorneys, 3300 Brunswick

⑦② Inventor:  
Application for anonymity

⑤④ Use of a ginkgo extract

The invention relates to the use of a  
dry extract of ginkgo biloba leaves for  
the treatment of metastatic cancer.

DE 38 32 056 A1

DE 38 32 056 A1

## Description

The invention relates to the use of a dry extract of ginkgo biloba leaves.

Under the trade name "Tebonin," the firm of Dr. Willmar Schwabe is bringing a preparation of natural substances onto the market as an injection and infusion solution, namely against cerebral and peripheral circulatory insufficiency and malnourishment. With this medicament the symptoms of vertigo, tinnitus, and, above all, vascular headaches and visual disturbances are improved in the case of dementia. In the case of vascular disturbances of hearing in the inner ear the medicament is for the ability to hear and understanding of speech. Capacity for attention and concentration and intellectual capacity will be increased. States of anxiety, depression, and neurological disturbances are improved.

This previously known medicament is, among other things, used in the form of infusion ampules, where one 25-ml infusion ampule contains 87.5 mg of dry extract of ginkgo biloba leaves for injection standardized to 21.0 mg of ginkgo flavonglycosides.

The invention consists of the use of a dry extract of ginkgo biloba leaves for the treatment of metastatic cancer.

Thorough investigations in cancer patients have shown that the known cytostatic chemotherapeutic agents in combination with ginkgo extracts exhibit a stronger effect in inhibiting cell growth than the chemotherapeutic agents alone.

In this case it is advantageous if said dry extract is administered as a preliminary infusion before the administration of cytostatic chemotherapeutic agents. In this case it has been shown that lower doses of the chemotherapeutic agents in association with ginkgo flavonglycosides exhibit a

greater inhibiting effect on the growth of the cancer than the combined application of different cytostatic agents in higher doses.

From this, the conclusion can be reached that ginkgo extracts have an enhancing effect on the action of various cytostatic agents in inhibiting the growth of the cancer.

## Claims

1. Use of a dry extract of ginkgo biloba leaves for the treatment of metastatic cancer.
2. Use according to the Claim 1 as preliminary infusion before the administration of cytostatic chemotherapeutic agents.
3. Use according to Claim 1 or 2 as infusion of 87.5 mg of said dry extract standardized to 21.0 mg of ginkgo flavonglycosides or 1 g of sorbide.